{"id": "HPRD50.d1.s0_HPRD50.d1.s0.p0", "text": "Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2", "text_with_entity_marker": "Identification of residues in the [E1]monocyte chemotactic protein-1[/E1] that contact the MCP-1 receptor, [E2]CCR2[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "monocyte chemotactic protein-1", "entity_1_idx": [[34, 64]], "entity_1_idx_in_text_with_entity_marker": [38, 68], "entity_1_type": "pm0117207", "entity_1_type_id": 3, "entity_2": "CCR2", "entity_2_idx": [[98, 102]], "entity_2_idx_in_text_with_entity_marker": [111, 115], "entity_2_type": "pm0111607", "entity_2_type_id": 4}], "directed": false, "reverse": false}
{"id": "HPRD50.d2.s1_HPRD50.d2.s1.p0", "text": "The formation of a functional single chain/subunit complex was not restricted to the FSH single chain/CG beta subunit since CG single chain interacts with the monomeric FSH beta subunit and exhibits FSH activity", "text_with_entity_marker": "The formation of a functional single chain/subunit complex was not restricted to the FSH single chain/[E1]CG beta[/E1] subunit since CG single chain interacts with the monomeric [E2]FSH beta[/E2] subunit and exhibits FSH activity", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CG beta", "entity_1_idx": [[102, 109]], "entity_1_idx_in_text_with_entity_marker": [106, 113], "entity_1_type": "pm0125097", "entity_1_type_id": 8, "entity_2": "FSH beta", "entity_2_idx": [[169, 177]], "entity_2_idx_in_text_with_entity_marker": [182, 190], "entity_2_type": "pm0104723", "entity_2_type_id": 9}], "directed": false, "reverse": false}
{"id": "HPRD50.d3.s0_HPRD50.d3.s0.p0", "text": "Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines", "text_with_entity_marker": "[E1]Interleukin-6[/E1] activates [E2]phosphatidylinositol-3 kinase[/E2], which inhibits apoptosis in human prostate cancer cell lines", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Interleukin-6", "entity_1_idx": [[0, 13]], "entity_1_idx_in_text_with_entity_marker": [4, 17], "entity_1_type": "pm0110911", "entity_1_type_id": 11, "entity_2": "phosphatidylinositol-3 kinase", "entity_2_idx": [[24, 53]], "entity_2_idx_in_text_with_entity_marker": [37, 66], "entity_2_type": "pm0104655||pm0110290||pm0120114||pm0122783||pm0124741", "entity_2_type_id": 12}], "directed": false, "reverse": false}
{"id": "HPRD50.d3.s2_HPRD50.d3.s2.p2", "text": "IL-6 promotes coprecipitation of p85 with gp130, the signal-transducing component of the IL-6 receptor", "text_with_entity_marker": "IL-6 promotes coprecipitation of p85 with [E1]gp130[/E1], the signal-transducing component of the [E2]IL-6 receptor[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp130", "entity_1_idx": [[42, 47]], "entity_1_idx_in_text_with_entity_marker": [46, 51], "entity_1_type": "pm0113266||pm0122272", "entity_1_type_id": 14, "entity_2": "IL-6 receptor", "entity_2_idx": [[89, 102]], "entity_2_idx_in_text_with_entity_marker": [102, 115], "entity_2_type": "pm0106299", "entity_2_type_id": 15}], "directed": false, "reverse": false}
{"id": "HPRD50.d4.s1_HPRD50.d4.s1.p5", "text": "Immobilized FGFR4 also bound FGF-8 besides FGF-1 and FGF-2", "text_with_entity_marker": "Immobilized FGFR4 also bound FGF-8 besides [E1]FGF-1[/E1] and [E2]FGF-2[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FGF-1", "entity_1_idx": [[43, 48]], "entity_1_idx_in_text_with_entity_marker": [47, 52], "entity_1_type": "pm0124654", "entity_1_type_id": 16, "entity_2": "FGF-2", "entity_2_idx": [[53, 58]], "entity_2_idx_in_text_with_entity_marker": [66, 71], "entity_2_type": "pm0106166", "entity_2_type_id": 17}], "directed": false, "reverse": false}
{"id": "HPRD50.d7.s2_HPRD50.d7.s2.p2", "text": "By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (NF-E2-related factor 2)", "text_with_entity_marker": "By electrophoretic mobility shift assay using the [E1]NF-E2[/E1]/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 ([E2]NF-E2-related factor 2[/E2])", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NF-E2", "entity_1_idx": [[50, 55]], "entity_1_idx_in_text_with_entity_marker": [54, 59], "entity_1_type": "pm0120477", "entity_1_type_id": 28, "entity_2": "NF-E2-related factor 2", "entity_2_idx": [[241, 263]], "entity_2_idx_in_text_with_entity_marker": [254, 276], "entity_2_type": "pm0105918", "entity_2_type_id": 30}], "directed": false, "reverse": false}
{"id": "HPRD50.d7.s2_HPRD50.d7.s2.p4", "text": "By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (NF-E2-related factor 2)", "text_with_entity_marker": "By electrophoretic mobility shift assay using the NF-E2/[E1]AP-1[/E1] site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 ([E2]NF-E2-related factor 2[/E2])", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "AP-1", "entity_1_idx": [[56, 60]], "entity_1_idx_in_text_with_entity_marker": [60, 64], "entity_1_type": "pm0103880", "entity_1_type_id": 29, "entity_2": "NF-E2-related factor 2", "entity_2_idx": [[241, 263]], "entity_2_idx_in_text_with_entity_marker": [254, 276], "entity_2_type": "pm0105918", "entity_2_type_id": 30}], "directed": false, "reverse": false}
{"id": "HPRD50.d15.s2_HPRD50.d15.s2.p2", "text": "beta 2 integrin, detected by anti-CD18 mAb, was coprecipitated with GPI-80 from human neutrophil lysates by a mAb to GPI-80", "text_with_entity_marker": "beta 2 integrin, detected by anti-CD18 mAb, was coprecipitated with [E1]GPI-80[/E1] from human neutrophil lysates by a mAb to [E2]GPI-80[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GPI-80", "entity_1_idx": [[68, 74]], "entity_1_idx_in_text_with_entity_marker": [72, 78], "entity_1_type": "pm0100260", "entity_1_type_id": 49, "entity_2": "GPI-80", "entity_2_idx": [[117, 123]], "entity_2_idx_in_text_with_entity_marker": [130, 136], "entity_2_type": "pm0100260", "entity_2_type_id": 49}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s1_HPRD50.d16.s1.p1", "text": "Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "text_with_entity_marker": "[E1]Gadd45a[/E1] (Gadd45), [E2]Gadd45b[/E2] (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45a", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "pm0112301", "entity_1_type_id": 54, "entity_2": "Gadd45b", "entity_2_idx": [[18, 25]], "entity_2_idx_in_text_with_entity_marker": [31, 38], "entity_2_type": "pm0114403", "entity_2_type_id": 51}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s4_HPRD50.d16.s4.p1", "text": "In this work, we show that Gadd45b and Gadd45g specifically interact with the Cdk1/CyclinB1 complex, but not with other Cdk/Cyclin complexes, in vitro and in vivo", "text_with_entity_marker": "In this work, we show that [E1]Gadd45b[/E1] and Gadd45g specifically interact with the [E2]Cdk1[/E2]/CyclinB1 complex, but not with other Cdk/Cyclin complexes, in vitro and in vivo", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gadd45b", "entity_1_idx": [[27, 34]], "entity_1_idx_in_text_with_entity_marker": [31, 38], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "Cdk1", "entity_2_idx": [[78, 82]], "entity_2_idx_in_text_with_entity_marker": [91, 95], "entity_2_type": "pm0113152", "entity_2_type_id": 53}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s5_HPRD50.d16.s5.p0", "text": "Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "text_with_entity_marker": "Data also has been obtained that [E1]Gadd45b[/E1] and [E2]Gadd45g[/E2], as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45b", "entity_1_idx": [[33, 40]], "entity_1_idx_in_text_with_entity_marker": [37, 44], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "Gadd45g", "entity_2_idx": [[45, 52]], "entity_2_idx_in_text_with_entity_marker": [58, 65], "entity_2_type": "pm0116690", "entity_2_type_id": 52}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s5_HPRD50.d16.s5.p8", "text": "Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "text_with_entity_marker": "Data also has been obtained that Gadd45b and Gadd45g, as well as [E1]GADD45a[/E1], interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the [E2]Cdk1[/E2]/cyclinB1 complex", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GADD45a", "entity_1_idx": [[65, 72]], "entity_1_idx_in_text_with_entity_marker": [69, 76], "entity_1_type": "pm0112301", "entity_1_type_id": 54, "entity_2": "Cdk1", "entity_2_idx": [[166, 170]], "entity_2_idx_in_text_with_entity_marker": [179, 183], "entity_2_type": "pm0113152", "entity_2_type_id": 53}], "directed": false, "reverse": false}
{"id": "HPRD50.d19.s1_HPRD50.d19.s1.p0", "text": "p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) interacting with transcription factors is able to increase their activity on target gene promoters", "text_with_entity_marker": "[E1]p300[/E1]/[E2]cAMP-response-element-binding-protein[/E2] ('CREB')-binding protein (CBP) interacting with transcription factors is able to increase their activity on target gene promoters", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p300", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0126787", "entity_1_type_id": 65, "entity_2": "cAMP-response-element-binding-protein", "entity_2_idx": [[5, 42]], "entity_2_idx_in_text_with_entity_marker": [18, 55], "entity_2_type": "pm0100874", "entity_2_type_id": 66}], "directed": false, "reverse": false}
{"id": "HPRD50.d19.s2_HPRD50.d19.s2.p3", "text": "Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, MEF2A and p300 form a ternary complex", "text_with_entity_marker": "Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and [E1]MEF2A[/E1], and our in vivo studies demonstrated that TR, [E2]MEF2A[/E2] and p300 form a ternary complex", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MEF2A", "entity_1_idx": [[105, 110]], "entity_1_idx_in_text_with_entity_marker": [109, 114], "entity_1_type": "pm0122391", "entity_1_type_id": 67, "entity_2": "MEF2A", "entity_2_idx": [[158, 163]], "entity_2_idx_in_text_with_entity_marker": [171, 176], "entity_2_type": "pm0122391", "entity_2_type_id": 67}], "directed": false, "reverse": false}
{"id": "HPRD50.d19.s2_HPRD50.d19.s2.p5", "text": "Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, MEF2A and p300 form a ternary complex", "text_with_entity_marker": "Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, [E1]MEF2A[/E1] and [E2]p300[/E2] form a ternary complex", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MEF2A", "entity_1_idx": [[158, 163]], "entity_1_idx_in_text_with_entity_marker": [162, 167], "entity_1_type": "pm0122391", "entity_1_type_id": 67, "entity_2": "p300", "entity_2_idx": [[168, 172]], "entity_2_idx_in_text_with_entity_marker": [181, 185], "entity_2_type": "pm0126787", "entity_2_type_id": 65}], "directed": false, "reverse": false}
{"id": "HPRD50.d20.s0_HPRD50.d20.s0.p0", "text": "The human Imp3 and Imp4 proteins form a ternary complex with hMpp10, which only interacts with the U3 snoRNA in 60-80S ribonucleoprotein complexes", "text_with_entity_marker": "The human [E1]Imp3[/E1] and [E2]Imp4[/E2] proteins form a ternary complex with hMpp10, which only interacts with the U3 snoRNA in 60-80S ribonucleoprotein complexes", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Imp3", "entity_1_idx": [[10, 14]], "entity_1_idx_in_text_with_entity_marker": [14, 18], "entity_1_type": "pm0100548||pm0102353||pm0121765", "entity_1_type_id": 68, "entity_2": "Imp4", "entity_2_idx": [[19, 23]], "entity_2_idx_in_text_with_entity_marker": [32, 36], "entity_2_type": "pm0104160||pm0117832", "entity_2_type_id": 69}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s4_HPRD50.d22.s4.p0", "text": "This work led to identification of a novel GTPase-activating protein (GAP) for Rho family GTPases", "text_with_entity_marker": "This work led to identification of a novel [E1]GTPase-activating protein[/E1] ([E2]GAP[/E2]) for Rho family GTPases", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GTPase-activating protein", "entity_1_idx": [[43, 68]], "entity_1_idx_in_text_with_entity_marker": [47, 72], "entity_1_type": "pm0112603", "entity_1_type_id": 74, "entity_2": "GAP", "entity_2_idx": [[70, 73]], "entity_2_idx_in_text_with_entity_marker": [83, 86], "entity_2_type": "pm0112603||pm0113293", "entity_2_type_id": 81}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s5_HPRD50.d22.s5.p0", "text": "The GAP domain shows high similarity to the recently cloned CdGAP and displays activity toward RhoA, Rac1, and Cdc42 in vitro", "text_with_entity_marker": "The GAP domain shows high similarity to the recently cloned [E1]CdGAP[/E1] and displays activity toward RhoA, [E2]Rac1[/E2], and Cdc42 in vitro", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CdGAP", "entity_1_idx": [[60, 65]], "entity_1_idx_in_text_with_entity_marker": [64, 69], "entity_1_type": "pm0102116", "entity_1_type_id": 82, "entity_2": "Rac1", "entity_2_idx": [[101, 105]], "entity_2_idx_in_text_with_entity_marker": [114, 118], "entity_2_type": "pm0109115", "entity_2_type_id": 83}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s7_HPRD50.d22.s7.p1", "text": "Expression of GC-GAP in 293T cells led to a reduction in active Rac1 and Cdc42 levels but not RhoA", "text_with_entity_marker": "Expression of [E1]GC-GAP[/E1] in 293T cells led to a reduction in active Rac1 and [E2]Cdc42[/E2] levels but not RhoA", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GC-GAP", "entity_1_idx": [[14, 20]], "entity_1_idx_in_text_with_entity_marker": [18, 24], "entity_1_type": "pm0122639", "entity_1_type_id": 73, "entity_2": "Cdc42", "entity_2_idx": [[73, 78]], "entity_2_idx_in_text_with_entity_marker": [86, 91], "entity_2_type": "pm0110789", "entity_2_type_id": 80}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p1", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between [E1]Plk1[/E1] and NudC, show that [E2]Plk1[/E2] phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Plk1", "entity_1_idx": [[46, 50]], "entity_1_idx_in_text_with_entity_marker": [50, 54], "entity_1_type": "pm0109061", "entity_1_type_id": 85, "entity_2": "Plk1", "entity_2_idx": [[71, 75]], "entity_2_idx_in_text_with_entity_marker": [84, 88], "entity_2_type": "pm0109061", "entity_2_type_id": 85}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p5", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between Plk1 and [E1]NudC[/E1], show that [E2]Plk1[/E2] phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NudC", "entity_1_idx": [[55, 59]], "entity_1_idx_in_text_with_entity_marker": [59, 63], "entity_1_type": "pm0116104", "entity_1_type_id": 86, "entity_2": "Plk1", "entity_2_idx": [[71, 75]], "entity_2_idx_in_text_with_entity_marker": [84, 88], "entity_2_type": "pm0109061", "entity_2_type_id": 85}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p9", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between Plk1 and NudC, show that [E1]Plk1[/E1] phosphorylates [E2]NudC[/E2] at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Plk1", "entity_1_idx": [[71, 75]], "entity_1_idx_in_text_with_entity_marker": [75, 79], "entity_1_type": "pm0109061", "entity_1_type_id": 85, "entity_2": "NudC", "entity_2_idx": [[91, 95]], "entity_2_idx_in_text_with_entity_marker": [104, 108], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p10", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between Plk1 and NudC, show that [E1]Plk1[/E1] phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that [E2]NudC[/E2] is also a substrate for Plk1 in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Plk1", "entity_1_idx": [[71, 75]], "entity_1_idx_in_text_with_entity_marker": [75, 79], "entity_1_type": "pm0109061", "entity_1_type_id": 85, "entity_2": "NudC", "entity_2_idx": [[168, 172]], "entity_2_idx_in_text_with_entity_marker": [181, 185], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d24.s1_HPRD50.d24.s1.p2", "text": "The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway", "text_with_entity_marker": "The sterol-independent regulatory element (SIRE) of the [E1]LDL receptor[/E1] (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the [E2]LDLR[/E2] gene through a cholesterol-independent pathway", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LDL receptor", "entity_1_idx": [[56, 68]], "entity_1_idx_in_text_with_entity_marker": [60, 72], "entity_1_type": "pm0125757", "entity_1_type_id": 88, "entity_2": "LDLR", "entity_2_idx": [[141, 145]], "entity_2_idx_in_text_with_entity_marker": [154, 158], "entity_2_type": "pm0125757", "entity_2_type_id": 88}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s2_HPRD50.d26.s2.p5", "text": "TBP-1 associates with the beta-domain of pVHL and complexes with pVHL and Hif1 alpha in vivo", "text_with_entity_marker": "TBP-1 associates with the beta-domain of pVHL and complexes with [E1]pVHL[/E1] and [E2]Hif1 alpha[/E2] in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pVHL", "entity_1_idx": [[65, 69]], "entity_1_idx_in_text_with_entity_marker": [69, 73], "entity_1_type": "pm0104236", "entity_1_type_id": 92, "entity_2": "Hif1 alpha", "entity_2_idx": [[74, 84]], "entity_2_idx_in_text_with_entity_marker": [87, 97], "entity_2_type": "pm0100197", "entity_2_type_id": 93}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s6_HPRD50.d26.s6.p3", "text": "A pVHL mutant containing a P154L substitution coimmunoprecipitates with Hif1 alpha, but not TBP-1, and does not promote degradation of Hif1 alpha", "text_with_entity_marker": "A pVHL mutant containing a P154L substitution coimmunoprecipitates with [E1]Hif1 alpha[/E1], but not [E2]TBP-1[/E2], and does not promote degradation of Hif1 alpha", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Hif1 alpha", "entity_1_idx": [[72, 82]], "entity_1_idx_in_text_with_entity_marker": [76, 86], "entity_1_type": "pm0100197", "entity_1_type_id": 93, "entity_2": "TBP-1", "entity_2_idx": [[92, 97]], "entity_2_idx_in_text_with_entity_marker": [105, 110], "entity_2_type": "pm0113245||pm0120764", "entity_2_type_id": 95}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s7_HPRD50.d26.s7.p1", "text": "Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors", "text_with_entity_marker": "Thus, the ability of [E1]pVHL[/E1] to degrade Hif1 alpha depends in part on its interaction with [E2]TBP-1[/E2] and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "pVHL", "entity_1_idx": [[21, 25]], "entity_1_idx_in_text_with_entity_marker": [25, 29], "entity_1_type": "pm0104236", "entity_1_type_id": 92, "entity_2": "TBP-1", "entity_2_idx": [[88, 93]], "entity_2_idx_in_text_with_entity_marker": [101, 106], "entity_2_type": "pm0113245||pm0120764", "entity_2_type_id": 95}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s7_HPRD50.d26.s7.p2", "text": "Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors", "text_with_entity_marker": "Thus, the ability of [E1]pVHL[/E1] to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for [E2]Hif1 alpha[/E2] stabilization in some pVHL-deficient tumors", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pVHL", "entity_1_idx": [[21, 25]], "entity_1_idx_in_text_with_entity_marker": [25, 29], "entity_1_type": "pm0104236", "entity_1_type_id": 92, "entity_2": "Hif1 alpha", "entity_2_idx": [[127, 137]], "entity_2_idx_in_text_with_entity_marker": [140, 150], "entity_2_type": "pm0100197", "entity_2_type_id": 93}], "directed": false, "reverse": false}
{"id": "HPRD50.d27.s0_HPRD50.d27.s0.p1", "text": "Pinin/DRS/memA interacts with SRp75, SRm300 and SRrp130 in corneal epithelial cells", "text_with_entity_marker": "[E1]Pinin[/E1]/DRS/memA interacts with [E2]SRp75[/E2], SRm300 and SRrp130 in corneal epithelial cells", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Pinin", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "pm0118763", "entity_1_type_id": 96, "entity_2": "SRp75", "entity_2_idx": [[30, 35]], "entity_2_idx_in_text_with_entity_marker": [43, 48], "entity_2_type": "pm0111657", "entity_2_type_id": 97}], "directed": false, "reverse": false}
{"id": "HPRD50.d27.s0_HPRD50.d27.s0.p3", "text": "Pinin/DRS/memA interacts with SRp75, SRm300 and SRrp130 in corneal epithelial cells", "text_with_entity_marker": "Pinin/[E1]DRS[/E1]/memA interacts with [E2]SRp75[/E2], SRm300 and SRrp130 in corneal epithelial cells", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "DRS", "entity_1_idx": [[6, 9]], "entity_1_idx_in_text_with_entity_marker": [10, 13], "entity_1_type": "pm0118763", "entity_1_type_id": 96, "entity_2": "SRp75", "entity_2_idx": [[30, 35]], "entity_2_idx_in_text_with_entity_marker": [43, 48], "entity_2_type": "pm0111657", "entity_2_type_id": 97}], "directed": false, "reverse": false}
{"id": "HPRD50.d28.s0_HPRD50.d28.s0.p1", "text": "We report that MSH2 (MutS homolog 2) protein interacts with the ATR (ATM- and Rad3-related) kinase to form a signaling module and regulate the phosphorylation of Chk1 and SMC1 (structure maintenance of chromosome 1)", "text_with_entity_marker": "We report that [E1]MSH2[/E1] (MutS homolog 2) protein interacts with the ATR (ATM- and Rad3-related) kinase to form a signaling module and regulate the phosphorylation of Chk1 and [E2]SMC1[/E2] (structure maintenance of chromosome 1)", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MSH2", "entity_1_idx": [[15, 19]], "entity_1_idx_in_text_with_entity_marker": [19, 23], "entity_1_type": "pm0121865", "entity_1_type_id": 99, "entity_2": "SMC1", "entity_2_idx": [[171, 175]], "entity_2_idx_in_text_with_entity_marker": [184, 188], "entity_2_type": "pm0116233", "entity_2_type_id": 101}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s1_HPRD50.d29.s1.p0", "text": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "text_with_entity_marker": "Here we show that [E1]Dnmt3a[/E1] interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme [E2]Ubc9[/E2] and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Dnmt3a", "entity_1_idx": [[18, 24]], "entity_1_idx_in_text_with_entity_marker": [22, 28], "entity_1_type": "pm0106301", "entity_1_type_id": 103, "entity_2": "Ubc9", "entity_2_idx": [[128, 132]], "entity_2_idx_in_text_with_entity_marker": [141, 145], "entity_2_type": "pm0110323", "entity_2_type_id": 105}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s1_HPRD50.d29.s1.p3", "text": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "text_with_entity_marker": "Here we show that [E1]Dnmt3a[/E1] interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, [E2]SUMO-1[/E2], to its target proteins", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Dnmt3a", "entity_1_idx": [[18, 24]], "entity_1_idx_in_text_with_entity_marker": [22, 28], "entity_1_type": "pm0106301", "entity_1_type_id": 103, "entity_2": "SUMO-1", "entity_2_idx": [[267, 273]], "entity_2_idx_in_text_with_entity_marker": [280, 286], "entity_2_type": "pm0108344", "entity_2_type_id": 104}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s1_HPRD50.d29.s1.p4", "text": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "text_with_entity_marker": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme [E1]Ubc9[/E1] and the E3 sumo ligases [E2]PIAS1[/E2] and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Ubc9", "entity_1_idx": [[128, 132]], "entity_1_idx_in_text_with_entity_marker": [132, 136], "entity_1_type": "pm0110323", "entity_1_type_id": 105, "entity_2": "PIAS1", "entity_2_idx": [[157, 162]], "entity_2_idx_in_text_with_entity_marker": [170, 175], "entity_2_type": "pm0117395", "entity_2_type_id": 106}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s0_HPRD50.d32.s0.p2", "text": "Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease", "text_with_entity_marker": "Differential binding of vascular cell-derived proteoglycans ([E1]perlecan[/E1], biglycan, decorin, and [E2]versican[/E2]) to the beta-amyloid protein of Alzheimer's disease", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "perlecan", "entity_1_idx": [[61, 69]], "entity_1_idx_in_text_with_entity_marker": [65, 73], "entity_1_type": "pm0116983", "entity_1_type_id": 114, "entity_2": "versican", "entity_2_idx": [[94, 102]], "entity_2_idx_in_text_with_entity_marker": [107, 115], "entity_2_type": "pm0106611", "entity_2_type_id": 117}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s0_HPRD50.d32.s0.p3", "text": "Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease", "text_with_entity_marker": "Differential binding of vascular cell-derived proteoglycans (perlecan, [E1]biglycan[/E1], [E2]decorin[/E2], and versican) to the beta-amyloid protein of Alzheimer's disease", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "biglycan", "entity_1_idx": [[71, 79]], "entity_1_idx_in_text_with_entity_marker": [75, 83], "entity_1_type": "pm0124379", "entity_1_type_id": 115, "entity_2": "decorin", "entity_2_idx": [[81, 88]], "entity_2_idx_in_text_with_entity_marker": [94, 101], "entity_2_type": "pm0108608", "entity_2_type_id": 116}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s1_HPRD50.d32.s1.p1", "text": "Previous studies have demonstrated the immunolocalization of perlecan, a specific heparan sulfate proteoglycan, to the beta-amyloid protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain", "text_with_entity_marker": "Previous studies have demonstrated the immunolocalization of [E1]perlecan[/E1], a specific heparan sulfate proteoglycan, to the [E2]beta-amyloid[/E2] protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "perlecan", "entity_1_idx": [[61, 69]], "entity_1_idx_in_text_with_entity_marker": [65, 73], "entity_1_type": "pm0116983", "entity_1_type_id": 114, "entity_2": "beta-amyloid", "entity_2_idx": [[119, 131]], "entity_2_idx_in_text_with_entity_marker": [132, 144], "entity_2_type": "beta-pm0104696", "entity_2_type_id": 119}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p14", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by [E1]perlecan[/E1], weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/[E2]PG-M[/E2], a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "perlecan", "entity_1_idx": [[85, 93]], "entity_1_idx_in_text_with_entity_marker": [89, 97], "entity_1_type": "pm0116983", "entity_1_type_id": 114, "entity_2": "PG-M", "entity_2_idx": [[201, 205]], "entity_2_idx_in_text_with_entity_marker": [214, 218], "entity_2_type": "pm0106611", "entity_2_type_id": 117}], "directed": false, "reverse": false}
{"id": "HPRD50.d36.s1_HPRD50.d36.s1.p1", "text": "These results suggest that tyrosyl-phosphorylated CD22 may be a substrate for PTP-1C regulates tyrosyl phosphorylation of CD22", "text_with_entity_marker": "These results suggest that tyrosyl-phosphorylated [E1]CD22[/E1] may be a substrate for PTP-1C regulates tyrosyl phosphorylation of [E2]CD22[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD22", "entity_1_idx": [[50, 54]], "entity_1_idx_in_text_with_entity_marker": [54, 58], "entity_1_type": "pm0119833", "entity_1_type_id": 135, "entity_2": "CD22", "entity_2_idx": [[122, 126]], "entity_2_idx_in_text_with_entity_marker": [135, 139], "entity_2_type": "pm0119833", "entity_2_type_id": 135}], "directed": false, "reverse": false}
{"id": "HPRD50.d36.s4_HPRD50.d36.s4.p0", "text": "Transient expression of CD22 and a null mutant of PTP-1C (PTP-1CM) in COS cells resulted in an increase in tyrosyl phosphorylation of CD22 and its interaction with PTP-1CM", "text_with_entity_marker": "Transient expression of [E1]CD22[/E1] and a null mutant of [E2]PTP-1C[/E2] (PTP-1CM) in COS cells resulted in an increase in tyrosyl phosphorylation of CD22 and its interaction with PTP-1CM", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD22", "entity_1_idx": [[24, 28]], "entity_1_idx_in_text_with_entity_marker": [28, 32], "entity_1_type": "pm0119833", "entity_1_type_id": 135, "entity_2": "PTP-1C", "entity_2_idx": [[50, 56]], "entity_2_idx_in_text_with_entity_marker": [63, 69], "entity_2_type": "pm0105676", "entity_2_type_id": 136}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p1", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving [E1]involucrin[/E1] cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, [E2]desmoplakin[/E2], elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "involucrin", "entity_1_idx": [[66, 76]], "entity_1_idx_in_text_with_entity_marker": [70, 80], "entity_1_type": "pm0104308", "entity_1_type_id": 139, "entity_2": "desmoplakin", "entity_2_idx": [[187, 198]], "entity_2_idx_in_text_with_entity_marker": [200, 211], "entity_2_type": "pm0110549", "entity_2_type_id": 141}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p12", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, [E1]elafin[/E1], keratins, members of the small proline-rich superfamily, [E2]loricrin[/E2], and unknown proteins related to the desmoplakin family", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "elafin", "entity_1_idx": [[200, 206]], "entity_1_idx_in_text_with_entity_marker": [204, 210], "entity_1_type": "pm0114270", "entity_1_type_id": 142, "entity_2": "loricrin", "entity_2_idx": [[265, 273]], "entity_2_idx_in_text_with_entity_marker": [278, 286], "entity_2_type": "pm0103809", "entity_2_type_id": 143}], "directed": false, "reverse": false}
{"id": "HPRD50.d41.s0_HPRD50.d41.s0.p0", "text": "We report here that PLZF, and a structurally similar transcriptional repressor, BCL-6, can interact with a variety of corepressor proteins in addition to SMRT, including the mSin3A protein and (for PLZF) histone deacetylase-1", "text_with_entity_marker": "We report here that PLZF, and a structurally similar transcriptional repressor, [E1]BCL-6[/E1], can interact with a variety of corepressor proteins in addition to SMRT, including the mSin3A protein and (for PLZF) [E2]histone deacetylase-1[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "BCL-6", "entity_1_idx": [[80, 85]], "entity_1_idx_in_text_with_entity_marker": [84, 89], "entity_1_type": "pm0100563", "entity_1_type_id": 150, "entity_2": "histone deacetylase-1", "entity_2_idx": [[204, 225]], "entity_2_idx_in_text_with_entity_marker": [217, 238], "entity_2_type": "pm0119729", "entity_2_type_id": 108}], "directed": false, "reverse": false}
